Alcon and RxSight announced a nonexclusive collaboration to develop a light-adjustable presbyopia-correcting IOL, according ...
Alcon and RxSight, Inc have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting ...
Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
MarketBeat on MSN
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook
Key Points Interested in RxSight, Inc.? Here are five stocks we like better. RxSight's preliminary Q2 sales fell 20% year ...
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for cataract patients.
Wellbeing Magazine on MSN
Is the light adjustable lens Estero’s best bet for custom cataract vision?
Imagine stepping onto the pickleball court and seeing every line sharp and bright—no glasses, just Florida sunshine. That ...
Aziz Mottiwala becomes RxSight CEO July 20 amid commercial challenges. The move follows the $200M Alcon deal for adjustable ...
RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the ...
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies; Collaboration aims to combine best-in-class ...
Despite near-term headwinds, RxSight has long-term upside from the Alcon royalty partnership, stronger margins and discounted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results